Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03954652
Other study ID # WG-Trio01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2019
Est. completion date October 1, 2022

Study information

Verified date October 2022
Source University Hospital Tuebingen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The GENOME FIRST APPROACH project will enroll patients (n = 450) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and the healthy parents of those affected for trio analysis (N in total 1350).


Description:

In the GENOME FIRST APPROACH (monocentric, prospective, open-label diagnostic) project, patients with molecularly undiagnosed diseases will diagnostically be analyzed by Whole Genome Sequencing (WGS)-trio analysis. The following questions will be leading the project: Primary: • Efficacy of WGS trio analysis in different clinical indications Secondary: - Systematically benchmark WGS analysis to detect genetic variations compared to WES and single nucleotide polymorphism (SNP) array analysis, - Expand the analysis from coding single-nucleotide variants (SNVs) to regulatory mutations, structural variants (SVs), and low complexity regions, - Validate the efficacy of clinical genome trio sequencing in a routine diagnostic setting, - Analyse whether 42x coverage has the potential to discover mosaicism as disease causing mechanism, - Further develop algorithms for integrative analyses of Trio-WGS data with Ribonucleic acid- sequencing (RNA-seq), - Identify de novo alterations and novel disease mechanisms, - Gain fundamental new insights into disease mechanisms and cellular biology, - Combine WGS with further Omics methods to improve genetic diagnostics of future rare disease patients, and - Explore overall financial costs and time to report conclusive data to the patients of the Trio-WGS approach compared to traditional multistep diagnostic approaches using single-gene, panel, whole-exome sequencing (WES) and chromosomal microarray (CMA) (SNP array, array-based comparative genomic hybridization (arrayCGH)) analysis. In addition, healthy parents of the subjects will be included in the project to perform parent-child (trio) analyzes.


Recruitment information / eligibility

Status Completed
Enrollment 1350
Est. completion date October 1, 2022
Est. primary completion date October 1, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Unclear molecular cause of the disease - Suspected genetic cause of the disease - Healthy parents of those affected for trio analysis Cohort 1: IQ < 70 with and without malformations, syndromic and non-syndromic Cohort 2: Retinitis pigmentosa, achromatopsy, Bardet-Biedl syndrome, Usher syndrome, congenital stationary night blindness, LCA, macula degeneration, rod/ cone dystrophies, opticus atrophy Cohort 3: Rare paediatric solid cancers as melanoma, carcinoma of the gastrointestinal tract, tumours of the salivary gland and pancreatic tumors in children. Exclusion Criteria: Cohort 1: Toxic causes (drugs, infections) Cohort 2: patients with non-genetic forms of blindness Cohort 3: adult cancer, blood cancer - Missing informed consent of the patient/ legal guardian - Missing samples of both parents - Previous WES or panel analysis-

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
WGS-Diagnostic
Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.

Locations

Country Name City State
Germany University Hospital Tübingen Tübingen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Full genomic sequence analysis carried out by Whole Genome Sequencing (WGS) Number of genomic variants in disease and health parents by WGS (a Next-Generation Sequencing Technology, NGS) Day 1
Secondary Genome sequencing Verification of the genetic causes of unclear genetic diseases by clinical genome sequencing Day 1
Secondary De novo alterations Number of de novo alterations in genome of the enrolled population Day 1
See also
  Status Clinical Trial Phase
Completed NCT04746794 - Early Detection of GEnetic Risk (EDGE) N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Not yet recruiting NCT06441942 - Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome
Terminated NCT04119596 - Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
Recruiting NCT04141462 - EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer N/A
Completed NCT02826330 - Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
Recruiting NCT05929976 - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Not yet recruiting NCT04620278 - Genetic Investigation of Cancer Predisposition
Active, not recruiting NCT02373709 - Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
Not yet recruiting NCT06089421 - Genetic Information Assistant in Telegenetics N/A
Completed NCT05975489 - Genetics in the Effect of Caffeine on Fat Oxidation N/A
Completed NCT04113239 - Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
Enrolling by invitation NCT04373525 - Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Completed NCT03362099 - Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) Phase 4
Recruiting NCT05857670 - Psyco Quality of Life and Procreation BRCA1/2
Active, not recruiting NCT04774445 - Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes N/A
Recruiting NCT05759143 - Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing N/A
Active, not recruiting NCT04920513 - Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
Active, not recruiting NCT04781205 - Genome Driven Primary Care Clinics - an RCT N/A